plerixafor has been researched along with cytarabine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 14 (93.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bridger, G; DiPersio, JF; Holt, MS; Ley, TJ; Nervi, B; Piwnica-Worms, D; Prior, JL; Ramirez, P; Rettig, MP; Ritchey, JK; Uy, GL | 1 |
Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
Andreeff, M; Hatanaka, Y; Hsu, FJ; Jin, L; Konopleva, M; Miida, T; Shi, YX; Shikami, M; Tabe, Y; Zeng, Z | 1 |
Bonferroni, M; Borra, A; Castellino, C; Celeghini, I; Di Marco, C; Fiore, F; Gallamini, A; Ghiglia, A; Grasso, M; Marenchino, D; Mattei, D; Mordini, N; Rapezzi, D; Sorasio, R; Strola, G | 1 |
Annesley, CE; Brown, P; Li, L; Magoon, D; Rau, RE; Sison, EA; Small, D | 1 |
Kong, P; Li, J; Ma, Y; Shen, Z; Zeng, D; Zhang, C; Zhang, X; Zhu, L; Zou, Z | 1 |
Han, AR; Kim, HJ; Kim, SH; Lee, JY; Min, WS; Park, G | 1 |
Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, X | 1 |
Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P | 1 |
Binner, M; Bornhäuser, M; Bray, LJ; Körner, Y; von Bonin, M; Werner, C | 1 |
Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
Han, AR; Hwang, HS; Kim, HJ; Lee, JY; Min, WS; Park, GS | 1 |
1 review(s) available for plerixafor and cytarabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for plerixafor and cytarabine
Article | Year |
---|---|
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Biomarkers; Cyclams; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Time Factors; Transplantation, Autologous | 2014 |
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation | 2017 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
9 other study(ies) available for plerixafor and cytarabine
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
Topics: Animals; Anti-HIV Agents; Antimetabolites, Antineoplastic; Apoptosis; Benzylamines; Bone Marrow; Cathepsin G; Cathepsins; Colony-Forming Units Assay; Cyclams; Cytarabine; Drug Synergism; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Protein Transport; Receptors, CXCR4; Serine Endopeptidases; Stromal Cells; Tumor Cells, Cultured | 2009 |
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Neoplasm Transplantation; Receptors, CXCR4; Transforming Growth Factor beta; Tumor Microenvironment | 2013 |
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Adhesion Molecules; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Coculture Techniques; Cyclams; Cytarabine; Heterocyclic Compounds; Heterografts; Humans; Infant; Infant, Newborn; Integrin alpha4beta1; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR; Receptors, CXCR4; Up-Regulation | 2014 |
[Effects of SDF-1/CXCR4 signal pathway blockade by AMD3100 on the adhesion of leukemia cells to osteoblast niche and the drug resistance of leukemia cells].
Topics: Apoptosis; Benzylamines; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Drug Resistance; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia; Mesenchymal Stem Cells; Osteoblasts; Receptors, CXCR4; Signal Transduction | 2015 |
A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzylamines; Bone Marrow Cells; Cell Movement; Chemokine CXCL12; Cyclams; Cytarabine; Female; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplasms, Experimental; Neoplastic Stem Cells; Receptors, CXCR4; Tumor Microenvironment | 2015 |
AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Biomimetic Materials; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Cytarabine; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Polystyrenes; Receptor Cross-Talk; Receptors, CXCR4; Stromal Cells | 2016 |
A three-dimensional
Topics: Benzylamines; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cyclams; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzylamines; Cell Line, Tumor; Cyclams; Cytarabine; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunomodulation; Immunotherapy; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Receptors, CXCR4; Tumor Microenvironment | 2019 |